Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
The Oncologist|June 7, 2022
Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant MesotheliomaYutaka Fujiwara, Yasuo Takahashi, Morihito Okada, et al.
Japanese Journal of Clinical Oncology|February 10, 2011
Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphismsYusuke Okuyama, Shoichi Hazama, Hiroshi Nozawa, et al.
British Journal of Haematology|December 23, 2003
Decrease of Smad4 gene expression in patients with essential thrombocythaemia may cause an escape from suppression of megakaryopoiesis by transforming growth factor-beta1Hiroyuki Kuroda, Takuya Matsunaga, Takeshi Terui, et al.
Cancer Chemotherapy and Pharmacology|July 17, 2016
Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumoursKan Yonemori, Kenji Tamura, Makoto Kodaira, et al.
Investigational New Drugs|January 11, 2017
Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I studyHideo Saka, Chiyoe Kitagawa, Yoshihito Kogure, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|February 28, 2022
Identifying Early Predictive Markers for Immune-Related Adverse Events in Nivolumab-Treated Patients with Renal Cell Carcinoma and Gastric CancerShinya Takada, Hidetaka Murooka, Kanae Tahatsu, et al.
Cancer Chemotherapy and Pharmacology|November 9, 2018
A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancerYasushi Sato, Tamotsu Sagawa, Hiroyuki Ohnuma, et al.
Frontiers in Immunology|July 26, 2023
Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case reportTamotsu Sagawa, Yasushi Sato, Hiroyuki Nagashima, et al.
Cancer Chemotherapy and Pharmacology|August 30, 2017
A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancerNaoki Uemura, Shohei Kikuchi, Yasushi Sato, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 25, 2016
Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective studyYasushi Sato, Hiroyuki Ohnuma, Takayuki Nobuoka, et al.
Pageof 4